Population
Patients with atrial fibrillation and end-stage renal disease
Comparison
Warfarin use vs non-use
Design
Review of studies
Answers are grounded in this paper and cite their sources.
Caution against routine warfarin in ESRD-AF due to higher hemorrhagic stroke risk; leaves open optimal anticoagulation pending randomized trials.
In the studies reviewed, warfarin use appears to have been associated with no change in the incidence of ischemic stroke in patients with atrial fibrillation and end-stage renal disease. However, from the studies reviewed, it does appear to be associated with a significantly higher risk of hemorrhagic stroke, with no significant difference in the risk of major bleeding, and with no change in mortality.
No takes yet. Share an insight, caveat, or question.
Randhawa et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: